Search | Clinical Trials Finder

Conditions: Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 385 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 9
States / cities: Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more

Conditions: Polycystic Ovary Syndrome, Metabolic Syndrome
Interventions: flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain
Interventions: Suzetrigine, DRSP/EE, NGM/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: JNJ-64155806 150 mg, Ethinylestradiol/drospirenone 0.02 mg/3 mg, COCP Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Polycystic Ovary Syndrome
Interventions: 3 mg DRSP/20 μg EE; Drug
Lead sponsor: Woman's; Other
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Overweight
Interventions: LY3437943, Ethinyl Estradiol, Drospirenone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: South Miami, Florida • San Antonio, Texas

Conditions: Infection, Human Immunodeficiency Virus, HIV Infections
Interventions: YASMIN, GSK2248761, Placebo; Drug · Other
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Acne Vulgaris
Interventions: drospirenone and ethinyl estradiol, Placebo tablet; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Contraception
Interventions: Levonorgestrel IUD (LCS, BAY86-5028), Yasmin (EE30/DRSP, BAY86-5131); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 24
States / cities: Tucson, Arizona • La Mesa, California • San Diego, California + 8 more

Conditions: Hidradenitis Suppurativa
Interventions: drospirenone and ethinyl estradiol (YAZ), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder
Interventions: Drospirenone-Ethinyl Estradiol Oral Tablet; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Polycystic Ovary Syndrome
Interventions: Yasmin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, LNG/EE, NGM/EE, NET/EE, DRSP/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acne Vulgaris
Interventions: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 534 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 27
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 23 more

Conditions: Cardiovascular Diseases
Interventions: Estradiol+MPA, Estradiol+Drospirenone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV), Simeprevir (SMV); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo; Drug · Behavioral · Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
Interventions: Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 206 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Seattle, Washington

Conditions: Contraception, Ovulation Inhibition, Contraceptives, Oral
Interventions: EE20/DRSP (BAY86-5300), EE20/DRSP (YAZ, BAY86-5300); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,887 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 85
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 74 more

Conditions: Polycystic Ovary Syndrome
Interventions: rosiglitazone, drospirenone/ethinyl estradiol; Drug
Lead sponsor: Silva Arslanian; Other
Eligibility: 10 Years to 20 Years · Female only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC); Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions: Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Drospirenone/Ethinylestradiol, Midazolam, JNJ-64530440; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

Metabolic Syndrome in PCOS: Precursors and Interventions

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

Binge Eating & Birth Control

Continuous Versus Cyclical OCP Use in PCOS

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Evaluate Safety and Efficacy of an OC Preparation vs Placebo for 6 Treatment Cycles in Women With Moderate Acne.

Effect of Estradiol+Drospirenone Versus Estradiol+MPA on Endothelial Function

To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440